JCR Pharmaceuticals (OTCMKTS:JCRRF – Get Free Report) is anticipated to post its resultson Thursday, July 30th. Analysts expect the company to announce earnings of ($0.0693) per share and revenue of $61.28 million for the quarter.
JCR Pharmaceuticals Price Performance
JCR Pharmaceuticals stock opened at $3.31 on Wednesday. JCR Pharmaceuticals has a twelve month low of $3.15 and a twelve month high of $3.31. The firm has a 50 day moving average price of $3.37 and a 200-day moving average price of $3.95.
About JCR Pharmaceuticals
JCR Pharmaceuticals Co, Ltd. is a Japan-based biotechnology company specializing in the development, production and commercialization of plasma-derived products and regenerative medicine solutions. The company focuses on manufacturing high-purity plasma proteins, including human serum albumin, immunoglobulins and coagulation factors, to support a range of therapeutic applications in hematology, immunology and critical care settings.
In its plasma-derived business, JCR leverages state-of-the-art fractionation and purification processes to supply products such as intravenous immunoglobulin and albumin formulations.
Featured Articles
- Five stocks we like better than JCR Pharmaceuticals
- These 3 Stocks Have Soared in 2026—Can They Keep Climbing?
- Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy Story
- Rambus: Another AI Phoenix Ready to Rise From the Ashes of Correction
- Chips & Clips: Memory Tariffs Rewire Tech Supply Chains
Receive News & Ratings for JCR Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for JCR Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
